← BIOMARIN PHARMACEUTICAL INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($630.2m) |
($117.0m)
+81.43%
|
($77.2m)
+34.03%
|
($23.8m)
+69.11%
|
$859.1m
+3702.40%
|
($64.1m)
-107.46%
|
$141.6m
+320.91%
|
$167.6m
+18.43%
|
$426.9m
+154.62%
|
$348.9m
-18.26%
|
— | |
| Depreciation, Depletion and Amortization | $96.9m | $87.9m | $95.7m | $105.3m | $105.2m | $108.0m | $102.0m | $104.4m | $96.4m | $79.6m | $153.0m | |
| Depreciation | $73.2m | $75.8m | $90.4m | $89.3m | $88.2m | $46.1m | $38.6m | $40.3m | $46.6m | $48.5m | $153.0m | |
| Amortization of Debt Issuance Costs and Discounts | $29.9m | $32.3m | $31.2m | $14.0m | $16.5m | $4.1m | $4.1m | $4.2m | $3.4m | $2.6m | — | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | — | $43.3m | $19.4m | — | |
| Capitalized Computer Software, Amortization | — | — | — | — | — | — | — | — | — | $7.4m | — | |
| Deferred Income Tax Expense (Benefit) | ($228.1m) | $44.5m | ($68.4m) | ($82.8m) | ($888.9m) | ($15.6m) | ($52.1m) | ($45.0m) | $56.1m | $48.7m | ($10.8m) | |
| Share-based Payment Arrangement, Noncash Expense | $134.6m | $140.3m | $148.8m | $159.9m | $189.7m | $197.3m | $196.3m | $207.1m | $201.6m | $181.4m | $215.3m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $59.5m | $33.5m | $35.9m | $42.7m | $44.6m | $45.8m | $54.3m | $76.3m | $77.6m | $56.0m | — | |
| Share-based Payment Arrangement, Expense | $134.6m | $140.3m | $148.8m | $159.9m | $189.7m | $197.3m | $196.3m | $207.1m | $201.6m | $181.4m | $215.3m | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | — | — | $12.6m | — | — | — | |
| Goodwill, Impairment Loss | — | — | — | — | $0 | $0 | — | — | — | — | $241.3m | |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | $599.1m | $0 | $0 | — | — | — | — | — | — | — | — | |
| Income (Loss) from Equity Method Investments | ($538k) | ($1.3m) | ($553k) | ($587k) | ($6k) | — | — | — | — | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $51.5m | $25.3m | $54.3m | $37.9m | $59.0m | ($65.6m) | $82.0m | $190.4m | $57.9m | $228.1m | ($117.9m) | |
| Increase (Decrease) in Inventories | $64.5m | $96.9m | $23.7m | $107.6m | $61.2m | $35.1m | $68.3m | $157.1m | $63.5m | $116.9m | ($32.1m) | |
| Inventory Write-down | — | — | — | — | $75.6m | $0 | $0 | — | — | $119.2m | — | |
| Gain (Loss) on Disposition of Other Assets | — | — | — | — | $59.5m | $0 | $108.0m | $0 | — | — | — | |
| Other Operating Income (Expense), Net | $4.9m | $8.0m | $2.2m | $6.9m | $7.1m | $11.8m | ($2.0m) | ($10.5m) | ($4.7m) | $9.0m | — | |
| Net Cash Provided by (Used in) Operating Activities | ($227.8m) |
($8.8m)
+96.16%
|
$20.2m
+330.76%
|
$48.3m
+138.83%
|
$85.4m
+76.88%
|
$304.5m
+256.75%
|
$175.9m
-42.24%
|
$159.3m
-9.46%
|
$572.8m
+259.69%
|
$828.0m
+44.54%
|
$857.1m
+3.51%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $148.4m | $199.2m | $144.6m | $145.0m | $114.3m | $95.6m | $121.0m | $96.7m | $85.4m | $103.0m | ($132.0m) | |
| Marketable Securities, Unrealized Gain (Loss) | $2.3m | — | — | — | — | — | — | — | — | — | — | |
| Payments to Acquire Investments | $699.7m | — | — | — | — | — | $611.8m | $868.5m | $410.2m | $355.9m | ($179.2m) | |
| Payments to Acquire Businesses, Net of Cash Acquired | $2.8m | $0 | $0 | — | — | — | — | — | — | — | ($5.4b) | |
| Payments for (Proceeds from) Other Investing Activities | $698k | $1.8m | $10k | $808k | $723k | $994k | $0 | $0 | ($1.1m) | $0 | — | |
| Net Cash Provided by (Used in) Investing Activities | ($484.0m) | ($305.5m) | $264.4m | ($31.0m) | ($53.6m) | ($366.3m) | ($20.0m) | ($111.2m) | $136.5m | ($414.2m) | ($4.7b) | |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common Stock | — | — | — | — | $50.0m | $0 | $0 | — | — | — | — | |
| Proceeds from Issuance of Common Stock | $712.9m | $0 | $0 | — | — | — | — | — | — | — | — | |
| Proceeds from (Payments for) Other Financing Activities | ($588k) | ($26k) | $0 | ($5.1m) | ($6.9m) | ($398k) | $0 | $0 | ($3.2m) | ($889k) | — | |
| Net Cash Provided by (Used in) Financing Activities | $727.1m |
$507.1m
-30.25%
|
($388.0m)
-176.51%
|
($74.7m)
+80.75%
|
$181.1m
+342.54%
|
($48k)
-100.03%
|
($18.6m)
-38754.17%
|
($18.7m)
-0.41%
|
($526.4m)
-2711.17%
|
($42.4m)
+91.95%
|
$3.6b
+8479.81%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($3.9m) | ($3.2m) | ($598k) | ($56.5m) | $211.7m | ($61.9m) | $137.3m | $30.6m | $187.7m | $368.8m | $873.7m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | $437.4m | $649.2m | $587.3m | $724.5m | $755.1m | $942.8m | $1.3b | $873.7m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $8.6m | $8.5m | $11.6m | $8.6m | $12.2m | $10.4m | $10.3m | $10.3m | $10.4m | $7.2m | — | |
| Income Taxes Paid, Net | $95.9m | $23.9m | $16.7m | $9.7m | $9.0m | $18.2m | $54.4m | $73.3m | $57.3m | $96.2m | — | |
| Additional Financial Items | ||||||||||||
| Asset Retirement Obligation, Accretion Expense | $107k | — | — | — | — | — | — | — | — | — | — | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | $0 | $714k | — | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | — | ($11.4m) | ($27.7m) | ($8.6m) | ($6.1m) | — | |
| Foreign Currency Transaction Gain (Loss), Unrealized | $14.5m | ($6.3m) | $17.8m | ($1.0m) | ($8.0m) | $1.8m | $14.3m | ($28.4m) | $16.8m | ($4.5m) | — | |
| Gain (Loss) on Disposition of Assets | — | — | — | — | $59.5m | $0 | $108.0m | $0 | $10.0m | $0 | — | |
| Gain (Loss) on Disposition of Intangible Assets | $0 | $125.0m | $50.0m | $25.0m | — | — | — | — | — | — | — | |
| Goodwill | $197.0m | $197.0m | $197.0m | $197.0m | $196.2m | $196.2m | $196.2m | $196.2m | $196.2m | $196.2m | $241.3m | |
| Income Tax Expense (Benefit) | ($200.8m) | $81.2m | ($65.5m) | ($71.0m) | ($901.4m) | ($11.3m) | $8.0m | $20.9m | $114.9m | $133.6m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $12.7m | $10.9m | — | |
| Investment Income, Interest | $7.5m | $14.9m | $22.8m | $22.7m | $16.6m | $10.5m | $18.0m | $58.3m | $74.9m | $74.9m | — | |
| Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax | $10.3m | ($5.1m) | ($2.0m) | $15.9m | — | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.